Login to Your Account



Clinic Roundup


Wednesday, August 29, 2012
• Evolva Holding SA, of Reinach, Switzerland, reported further data for the first 32 patients enrolled in its Phase IIa study of EV-077, a reversible antagonist of isoprostanes and prostanoids, showing that, when given orally to Type II diabetes patients, the drug provided antiplatelet activity, reduced exercise-induced proteinuria and increased forearm blood flow.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription